Last reviewed · How we verify
Evolocumab combined with statins
Evolocumab is a monoclonal antibody that inhibits PCSK9, allowing increased clearance of LDL cholesterol from the bloodstream, and is combined with statins to achieve greater LDL-lowering efficacy.
Evolocumab is a monoclonal antibody that inhibits PCSK9, allowing increased clearance of LDL cholesterol from the bloodstream, and is combined with statins to achieve greater LDL-lowering efficacy. Used for Hypercholesterolemia (primary and secondary prevention of cardiovascular events), Familial hypercholesterolemia.
At a glance
| Generic name | Evolocumab combined with statins |
|---|---|
| Also known as | drug1 |
| Sponsor | Zibo Central Hospital |
| Drug class | PCSK9 inhibitor (monoclonal antibody) |
| Target | PCSK9 |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Evolocumab binds to proprotein convertase subtilisin/kexin type 9 (PCSK9), a protein that normally degrades LDL receptors on hepatocytes. By blocking PCSK9, evolocumab preserves LDL receptors on the liver surface, enabling more efficient removal of LDL cholesterol from circulation. When combined with statins, which reduce cholesterol synthesis, the dual mechanism produces additive LDL-lowering effects beyond either agent alone.
Approved indications
- Hypercholesterolemia (primary and secondary prevention of cardiovascular events)
- Familial hypercholesterolemia
Common side effects
- Injection site reactions
- Nasopharyngitis
- Upper respiratory tract infection
- Muscle pain or myalgia
- Headache
Key clinical trials
- Cholesterol Disruption in Combination With the Standard of Care in Patients With Advanced Pancreatic Adenocarcinoma (EARLY_PHASE1)
- Efficacy and Safety of Early Combined Therapy With PCSK9 Inhibitors and Statins in Acute Ischemic Stroke (PHASE2, PHASE3)
- Multicenter Real-World Cohort Study Evaluating the Impact of Early Intensive Lipid-Lowering Therapy on the Prognosis of Acute Coronary Syndrome Patients(ELITE-ACS)
- Efficacy and Safety of Pitavastatin and PCSK9 Inhibitors in Liver Transplant Patients (PHASE4)
- Effect of Very Early and Rapid Lowering Cholesterol With Evolocumab on Left Ventricular Remodeling in Patients With Anterior STEMI Undergoing Primary PCI (PHASE4)
- Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (PHASE3)
- Efficacy and Safety of Bempedoic Acid in Association With Anti-PCSK9 and Ezetimibe in Statin-intolerant Patients (PHASE4)
- Effect of Combined Lipid-lowering Therapy on Atherosclerotic Plaque Vulnerability in Patients With ACS (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |